In a Placebo-Controlled 36-Week Phase 2 Trial, Treatment with Mgl-3196 Compared to Placebo Results in Significant Reductions in Hepatic Fat (MRI-PDFF), Liver Enzymes, Fibrosis Biomarkers, Atherogenic Lipids, and Improvement in Nash on Serial Liver Biopsy
Publication
, Conference
Harrison, SA; Guy, CD; Bashir, M; Frias, JP; Alkhouri, N; Baum, S; Taub, RA; Moylan, CA; Bansal, MB; Neuschwander-Tetri, BA; Moussa, S
Published in: HEPATOLOGY
October 1, 2018
Duke Scholars
Published In
HEPATOLOGY
EISSN
1527-3350
ISSN
0270-9139
Publication Date
October 1, 2018
Volume
68
Start / End Page
9A / 10A
Location
San Francisco, CA
Publisher
WILEY
Conference Name
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics
Citation
APA
Chicago
ICMJE
MLA
NLM
Harrison, S. A., Guy, C. D., Bashir, M., Frias, J. P., Alkhouri, N., Baum, S., … Moussa, S. (2018). In a Placebo-Controlled 36-Week Phase 2 Trial, Treatment with Mgl-3196 Compared to Placebo Results in Significant Reductions in Hepatic Fat (MRI-PDFF), Liver Enzymes, Fibrosis Biomarkers, Atherogenic Lipids, and Improvement in Nash on Serial Liver Biopsy. In HEPATOLOGY (Vol. 68, pp. 9A-10A). San Francisco, CA: WILEY.
Harrison, Stephen A., Cynthia D. Guy, Mustafa Bashir, Juan Pablo Frias, Naim Alkhouri, Seth Baum, Rebecca A. Taub, et al. “In a Placebo-Controlled 36-Week Phase 2 Trial, Treatment with Mgl-3196 Compared to Placebo Results in Significant Reductions in Hepatic Fat (MRI-PDFF), Liver Enzymes, Fibrosis Biomarkers, Atherogenic Lipids, and Improvement in Nash on Serial Liver Biopsy.” In HEPATOLOGY, 68:9A-10A. WILEY, 2018.
Harrison SA, Guy CD, Bashir M, Frias JP, Alkhouri N, Baum S, et al. In a Placebo-Controlled 36-Week Phase 2 Trial, Treatment with Mgl-3196 Compared to Placebo Results in Significant Reductions in Hepatic Fat (MRI-PDFF), Liver Enzymes, Fibrosis Biomarkers, Atherogenic Lipids, and Improvement in Nash on Serial Liver Biopsy. In: HEPATOLOGY. WILEY; 2018. p. 9A-10A.
Harrison, Stephen A., et al. “In a Placebo-Controlled 36-Week Phase 2 Trial, Treatment with Mgl-3196 Compared to Placebo Results in Significant Reductions in Hepatic Fat (MRI-PDFF), Liver Enzymes, Fibrosis Biomarkers, Atherogenic Lipids, and Improvement in Nash on Serial Liver Biopsy.” HEPATOLOGY, vol. 68, WILEY, 2018, pp. 9A-10A.
Harrison SA, Guy CD, Bashir M, Frias JP, Alkhouri N, Baum S, Taub RA, Moylan CA, Bansal MB, Neuschwander-Tetri BA, Moussa S. In a Placebo-Controlled 36-Week Phase 2 Trial, Treatment with Mgl-3196 Compared to Placebo Results in Significant Reductions in Hepatic Fat (MRI-PDFF), Liver Enzymes, Fibrosis Biomarkers, Atherogenic Lipids, and Improvement in Nash on Serial Liver Biopsy. HEPATOLOGY. WILEY; 2018. p. 9A-10A.
Published In
HEPATOLOGY
EISSN
1527-3350
ISSN
0270-9139
Publication Date
October 1, 2018
Volume
68
Start / End Page
9A / 10A
Location
San Francisco, CA
Publisher
WILEY
Conference Name
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics